Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TRDA Stock Price Chart Interactive Chart >
TRDA Price/Volume Stats
| Current price | $6.00 | 52-week high | $36.85 |
| Prev. close | $6.12 | 52-week low | $5.12 |
| Day low | $5.62 | Volume | 42,400 |
| Day high | $6.20 | Avg. volume | 94,506 |
| 50-day MA | $7.63 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 188.20M |
Entrada Therapeutics, Inc. (TRDA) Company Bio
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest TRDA News From Around the Web
Below are the latest news stories about Entrada Therapeutics Inc that investors may wish to consider to help them evaluate TRDA as an investment opportunity.
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care ConferenceBOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Monday, March 7, 2022 at 9:10 a.m. Eastern Time. |
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ...Investment company 5AM Venture Management, LLC (Current Portfolio) buys Pear Therapeutics Inc, Entrada Therapeutics Inc, sells Crinetics Pharmaceuticals Inc, Avidity Biosciences Inc, Silverback Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 5AM Venture Management, LLC. |
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General CounselBOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. “We are thrilled to recognize the appointment of Jared to General Counsel,” said Dipal Doshi, President and Chief Executive Officer of Entra |
Entrada Therapeutics (NASDAQ:TRDA) Trading Up 6.9%Shares of Entrada Therapeutics Inc (NASDAQ:TRDA) were up 6.9% during mid-day trading on Thursday . The company traded as high as $17.27 and last traded at $17.16. Approximately 2,764 shares were traded during trading, a decline of 99% from the average daily volume of 259,330 shares. The stock had previously closed at $16.05. A number [] |
TRDA Price Returns
| 1-mo | -10.45% |
| 3-mo | N/A |
| 6-mo | -75.13% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -64.95% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...